Renal and mesenteric artery intervention — the angioplasty and stenting for renal artery stenosis, renal denervation for hypertension, and mesenteric ischemia treatment — creates specialized peripheral vascular intervention markets, with the Peripheral Angioplasty Market reflecting renovascular and visceral vascular intervention as commercially important specialty segments.

Renal artery stenting controversy — the CORAL and ASTRAL trials failing to demonstrate benefit of renal artery stenting over medical therapy for atherosclerotic renal artery stenosis — dramatically reduced the renal stenting market from its peak. The current limited renal stenting market focused on fibromuscular dysplasia (angioplasty without stenting typically sufficient), flash pulmonary edema renal ischemia, and bilateral renal artery stenosis with uncontrolled hypertension and renal impairment.

Renal denervation for hypertension — the Medtronic Symplicity Spyral catheter, Paradise (ReCor Medical/Otsuka) intravascular ultrasound renal denervation, and SoniVie ultrasound renal denervation representing the catheter-based sympathetic nervous system ablation market for resistant hypertension. The FDA approval of the Paradise system for resistant hypertension based on RADIANCE-HTN TRIO trial creating the new renal denervation commercial market.

Mesenteric artery intervention — the angioplasty and stenting for chronic mesenteric ischemia (intestinal angina) and acute mesenteric ischemia — represents a small but important vascular intervention market. The highly specialized nature of mesenteric stenting requiring advanced endovascular skills limiting practice to high-volume vascular centers.

Do you think renal denervation for hypertension will achieve mainstream clinical adoption, and what would be the commercial market scale if resistant hypertension represents the primary indication?

FAQ

What happened to the renal artery stenting market? Renal artery stenting history: widely performed in 1990s-2000s for atherosclerotic renovascular hypertension; ASTRAL trial (2009): stenting plus medical therapy versus medical therapy alone — no benefit in BP, renal function, or cardiovascular events; CORAL trial (2014): similar negative results; outcome: dramatic reduction in renal stenting procedures; current use: highly selective (flash pulmonary edema syndrome, bilateral disease with severe hypertension and renal impairment, fibromuscular dysplasia — balloon only); renal stenting market now approximately 90% smaller than peak; remaining use: primarily FMD (angioplasty) and selected atherosclerotic cases.

What is renal denervation and what is the current evidence? Renal denervation (RDN): catheter-based ablation of renal sympathetic nerves surrounding renal artery; reduces sympathetic nervous system tone and blood pressure; Medtronic Symplicity Spyral: radiofrequency ablation; ReCor Paradise: intravascular ultrasound (iRDN); pivotal trials (sham-controlled): SPYRAL-HTN, RADIANCE-HTN TRIO; Paradise FDA approved January 2024 for resistant hypertension; blood pressure reduction: approximately eight to ten mmHg systolic in sham-controlled trials; indication: uncontrolled hypertension despite three or more medications including diuretic; commercial launch beginning; uncertain adoption given modest BP benefit and lifetime durability questions.

#PeripheralAngioplasty #RenalArtery #RenalDenervation #ParadiseRDN #RenovascularHypertension #MesentericIntervention